Is CVS Health Stock a Bad-News Buy?

Shares of CVS Health (NYSE: CVS) person been declining precocious arsenic a perchance lower-than-expected summation successful Medicare Advantage rates has investors disquieted astir companies with vulnerability to wellness insurance. For CVS, wellness security is so a ample portion of its concern arsenic it owns Aetna, which serves millions of radical passim the country.

Is CVS Health banal worthy buying close now, connected weakness, contempt immoderate concerning developments successful the healthcare sector, oregon is it excessively risky to adhd it to your portfolio today?

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

The Trump medication has projected minimal changes to Medicare Advantage rates for 2027, calling for an summation of conscionable 0.09% (analysts were expecting a maturation complaint betwixt 4% and 6%). More than one-third of CVS' gross comes from its healthcare benefits segment, which includes Aetna. Potentially crippling its maturation successful specified a important conception tin beryllium peculiarly problematic for a healthcare institution specified arsenic CVS, which mostly doesn't turn astatine a accelerated complaint to statesman with. In 2024, the institution generated astir $373 cardinal successful revenue, but its year-over-year maturation complaint was conscionable implicit 4%.

Another occupation for the concern is that aesculapian costs person been rising, and chipping distant astatine its margins successful the process. CVS typically generates single-digit nett margins, leaving small country for error. If costs proceed to creep up and determination isn't a worldly summation successful sales, past that tin spell catastrophe for its bottommost line. In its astir precocious reported quarter, which ended connected Sept. 30, 2025, CVS incurred a nett nonaccomplishment of conscionable nether $4 cardinal owed to goodwill impairment charges, which totaled $5.7 billion.

In 2025, shares of CVS Health roseate a staggering 77%, arsenic investors were bullish connected the company's turnaround efforts nether caller CEO David Joyner, who took implicit successful October 2024. But with aggregate imaginable headwinds to interest about, this is not a banal I'd consciousness comfy holding connected to. The wellness security manufacture is coming nether pressure, and CVS' pharmacy concern isn't each that breathtaking either, particularly arsenic consumers person much ways to bargain pharmaceutical products online these days.

The banal whitethorn look similar a inexpensive buy, trading astatine a guardant price-to-earnings aggregate of 10 (based connected expert expectations), but the broader macroeconomic issues are excessively concerning to ignore. Without overmuch amended margins oregon astatine slightest much appealing maturation prospects, CVS simply doesn't marque for an enticing bargain close now. As of Monday, the banal was down 5% since the commencement of the year, and I wouldn't beryllium amazed to spot it autumn further successful the weeks and months ahead.